OR-AIRSHIP
29.10.2020 09:32:07 CET | Business Wire | Press release
Customer engagement company Airship today detailed the amazing success three brand marketers have achieved using Airship Journeys to more quickly and easily improve the business impact of cross-channel customer journeys. The customer journeys these marketers have optimized have driven double- and even triple-digit percentage performance improvements over baselines established by control groups.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201029005340/en/
Airship Journeys combines everything marketers need to create, evaluate, test and optimize cross-channel customer engagement journeys in a single, intuitive visual UI. Only Airship Journeys allows marketers to zoom in from glanceable, color-coded visualizations of journey performance against business goals and baselines, to view and optimize any underlying message with A/B testing.
As the largest professional social network and digital distribution platform for musicians and other creative types, Vampr has created numerous journeys since selecting Airship in August 2020. A recently launched reactivation journey targets app users who have been inactive for five days with a series of three push notifications and a final email within two weeks, and has been found to reactivate users at a 277 percent higher rate than those in the control group.
“My goal is to drive critical business KPIs by getting users to complete their profiles, connect with nearby creatives, add their original songs and videos, and much more — 90 percent of the time I’m using Airship Journeys to optimize these user experiences,” said Jessy Trengove, head of insights, Vampr. “By being able to easily see journey performance against baseline metrics and control groups, I’m more easily able to achieve the goals that make a real difference to the business.”
On Black Friday, J. C. Penney Company, Inc. used Airship Journeys to transform a one-message cart abandonment automation into a two-message journey and found significant lift in completed purchases. This cart abandonment journey now shows an all-time increase of 40 percent higher purchase completion rates over the control group baseline. JCP reactivation messages spread across three separate automations are now being combined into a single journey, enabling a goal-based view of business impact rather than trying to draw conclusions by comparing each message’s engagement metrics.
“With Airship Journeys, we can see where each customer comes into and progresses through each phase and can more easily A/B test any message in the journey to optimize timing, triggers, copy and content,” said Haley Welmon, owned media specialist, JCPenney. “Airship Journeys control groups and baselines help us make decisions and increase revenue more quickly, so we can maximize our success and ensure that what we think is the best experience for the customer, actually is.”
In hospitality, in their mobile app, Radisson Hotel Group has created a cart abandonment journey series spanning three messages over four days — the first of which guarantees the room’s rate — driving an 11 percent lift in completed reservations over the control group.
Tune in to the webinar, “Creating Extraordinary Customer Journeys with a Culture of Experimentation,” live Thursday, October 29 at 10am PDT / 1pm EDT / 5pm GMT / 6pm CET (recording available to registrants), and learn how to gain advantage by experimenting, testing and optimizing critical cross-channel customer journeys.
“It’s so gratifying to see how quickly brands have realized substantial business gains due to the powerful way we’ve reinvented cross-channel journeys for the mobile era,” said Brett Caine, CEO and president, Airship. “Engaging customers with in-the-moment relevancy across digital channels has never been more important, and small improvements can drive big results. Airship Journeys brings breakthrough simplicity to the entire process and speeds insights-to-optimization to accelerate revenue growth.”
Recently, Airship was named a Leader in “The Forrester Wave™: Mobile Engagement Automation, Q3 2020 ,” receiving the highest score in the Strategy category (tied) and the second highest score in the Current Offering category.
About Airship
Thousands of the world’s leading brands rely on Airship to spark closer connections with their customers through highly contextual and relevant interactions. Only Airship’s Customer Engagement Platform takes a mobile-first, data-led approach that enables brands to focus on individuals and their needs, not which marketing channels to use. Airship makes it much simpler and more effective to grow customer lifetime value in the omnichannel era.
With trillions of interactions intelligently orchestrated across mobile apps, mobile wallet, SMS, websites, and email, Airship optimizes the entire customer journey across all digital touchpoints at scale.
For more information, visit www.airship.com , read our blog or follow us on Twitter , LinkedIn and Facebook .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201029005340/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
